Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma

Resistance to checkpoint-blockade treatments is a challenge in the clinic. Both primary and acquired resistance have become major obstacles, greatly limiting the long-lasting effects and wide application of blockade therapy. Many patients with metastatic melanoma eventually require further therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Guilan, Scott, Megan, Mangiamele, Cathryn G., Heller, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695203/
https://www.ncbi.nlm.nih.gov/pubmed/36365247
http://dx.doi.org/10.3390/pharmaceutics14112429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695203/
https://www.ncbi.nlm.nih.gov/pubmed/36365247
http://dx.doi.org/10.3390/pharmaceutics14112429

Ejemplares similares